- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy ; volume:23 ; number:1 ; day:8 ; month:5 ; year:2023 ; pages:1-22 ; date:12.2023
Cancer cell international ; 23, Heft 1 (8.5.2023), 1-22, 12.2023
- Creator
-
Hadiloo, Kaveh
Tahmasebi, Safa
Esmaeilzadeh, Abdolreza
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-023-02923-9
- URN
-
urn:nbn:de:101:1-2023090708233882071530
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hadiloo, Kaveh
- Tahmasebi, Safa
- Esmaeilzadeh, Abdolreza
- SpringerLink (Online service)
Other Objects (12)
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy